Help us: Donate
Follow us on:
×

Menu

Back

Tag: Ending Age-Related Diseases 2021

Terry Grossman
In this interview at our fourth annual Ending Age-Related Diseases conference, Elena Milova and Terry Grossman discuss his longevity clinic and how current medicine deals with the problems of aging. Script Elena: Greetings to the participants of Ending Age-Related Diseases 2021. This conference brings together thought leaders and researchers working on rejuvenation biotechnology with the...
EARD2021 Opening
In his introductory speech for our fourth annual Ending Age-Related Diseases conference, Lifespan.io president Keith Comito discusses the epic of Gilgamesh and how it relates to our modern quest of curing the diseases of aging. Script Good morning, and welcome to the fouth annual Ending Age-Related Diseases conference, and I hope you all are healthy...
Last chance to get a cheaper conference ticket
On August 19-22, join us online for our fourth annual conference, Ending Age-Related Diseases 2021, the #1 rejuvenation and life extension event! Four amazing days of aging research and biotech investment The format for this year sees us looking at the rejuvenation biotechnology industry as an ecosystem. To help visualize this, each of the four...
Ending Age-Related Diseases Conference 2021
August 19-22 sees the arrival of the annual Ending Age-Related Diseases conference, where we will discuss progress in the development of diagnostics for aging along with drugs and therapies for healthy life extension. The conference will be virtual this year due to the current global pandemic, which means you can join us from the comfort...
Facebook Post Announce
The #1 Event for Rejuvenation Biotechnology and Life Extension We at Lifespan.io are excited to announce our fourth annual Ending Age-Related Diseases Conference, EARD2021. The conference will take place virtually on August 19-22, 2021 and will focus on four traditional themes: the mechanisms of aging, rejuvenation human trials, biomarkers of aging, and investment matters. We...